Jørgen Bjerggaard Jensen
Clinical trials sponsored by Jørgen Bjerggaard Jensen, explained in plain language.
-
Blood test triggers early immunotherapy in bladder cancer trial
Disease control OngoingThis study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. …
Phase: PHASE2 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a shorter bladder cancer treatment time cut side effects?
Symptom relief OngoingThis study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based …
Phase: PHASE4 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC